Cystadenocarcinoma, Serous
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to analyse the promoter methylation status of the gene O6-methylguanine-DNA methyltransferase (MGMT) in malignant effusions, with focus on serous carcinoma.
|
31808217 |
2020 |
Intrahepatic Cholangiocarcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
The cell-proliferation assay and colony-formation assay were applied to evaluate proliferation ability, while methylation-specific PCR were used to detect the methylation status of the MGMT promoter CpG island in ICC tissues and cells.
|
31264147 |
2020 |
High grade serous carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT methylation at all four cytosine-guanine dinucleotide sites examined was detected in only 2/81 (2%) specimens, consisting of a high-grade serous carcinoma with high frequency of methylation, and a breast carcinoma with low methylation frequency.
|
31808217 |
2020 |
Goiter
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The resulting areas under the receiver operating characteristic (ROC) curve were 0.78 for MGMT (d) for PTC versus goiter samples that can represent the overall ability of MGMT (d) methylation status to discriminate between PTC and goiter patients.
|
31127647 |
2019 |
Spina Bifida Cystica
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Bisulfite sequencing polymerase chain reaction for MGMT promoter methylation demonstrated that almost all CpG sites in the MGMT promoter remained unmethylated in both spina bifida aperta rats and normal controls, and there was no significant difference in methylation level between the two groups on either E14 or E18.
|
30531021 |
2019 |
Adenocarcinoma of rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
O6-methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Rectal Adenocarcinoma After Chemoradiotherapy Treatment: Clinical Implications
|
31199091 |
2019 |
Lichen Planus, Oral
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genotyping of the C>T allele of rs16906252, predictor of O16-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, in erosive atrophic lesions of oral lichen planus.
|
31373397 |
2019 |
Squamous intraepithelial lesion
|
0.010 |
PosttranslationalModification
|
phenotype |
BEFREE |
Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis.
|
31574102 |
2019 |
Benign neoplasm of breast
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation was identified in 18.5% of MBT and 0.0% of the BBT (P = 0.01).
|
30938887 |
2019 |
Early infantile epileptic encephalopathy with suppression bursts
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
RPA VI (p = 0.048) and absence of MGMT methylation (p = 0.001) worsened OS significantly.
|
31054101 |
2019 |
Well Differentiated Pancreatic Endocrine Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.
|
30310970 |
2019 |
Opitz GBBB Syndrome, X-Linked
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
RPA VI (p = 0.048) and absence of MGMT methylation (p = 0.001) worsened OS significantly.
|
31054101 |
2019 |
Intellectual Disability
|
0.010 |
Biomarker
|
group |
BEFREE |
Immunohistochemical staining was performed against H3K27M, H3K27me3, EZH2, EED, mutant isocitrate dehydrogenase 1 (IDH1), α-thalassemia X-linked intellectual disability (ATRX), p53, O6-methylguanine-DNA methyltransferase (MGMT), and Ki-67 antibodies.
|
31096221 |
2019 |
HIV Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Promoter hypermethylation of TIMP3 and MGMT was detected in women with CIN recurrence and without CIN recurrence independent of HIV infection with significant difference between groups (p = 0.04 and p = 0.02, respectively).
|
30218185 |
2018 |
Dental Fluorosis, Acquired
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The mRNA levels of MGMT and MLH1 genes from the patients in fluorosis region were lower than those of a control group, and also showed a positive correlation with the severity of fluorosis.
|
30262283 |
2018 |
Rectal Neoplasms
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
In the present study we aimed to analyze the methylation status of MGMT and ERCC1 promoter regions in blood and tissue of patients with benign and malignant rectal tumors.
|
29080834 |
2018 |
Alveolar rhabdomyosarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Biopsy results suggested alveolar rhabdomyosarcoma bearing a methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter.
|
28834127 |
2018 |
Actinic cheilitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
MGMT promoter methylation and 1p/19q co-deletion might not be the ideal biomarkers for TMZ treatment in TC/AC patients.
|
29914531 |
2018 |
Childhood Alveolar Rhabdomyosarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Biopsy results suggested alveolar rhabdomyosarcoma bearing a methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter.
|
28834127 |
2018 |
Carcinoid tumor no ICD-O subtype
|
0.010 |
PosttranslationalModification
|
phenotype |
BEFREE |
MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.
|
29914531 |
2018 |
Large cell neuroendocrine carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Currently, the status of MGMT promoter methylation and 1p/19q co-deletion in pulmonary carcinoid (PC) and large-cell neuroendocrine carcinoma (LCNEC) is not reported.
|
29914531 |
2018 |
Low Grade Squamous Intraepithelial Neoplasia
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
For triage of low-grade squamous intraepithelial lesion (LSIL), gene methylation increased specificity from 4.0% of HR-HPV detection to 30.8% of MGMT (χ<sup>2</sup> = 9.873, P = 0.002) and to 50.0% of C13ORF18 (χ<sup>2</sup> = 21.814, P = 0.001).
|
29664054 |
2018 |
WHO Grade II Glioma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
This is the first study, to our knowledge, to validate the prognostic importance of MGMT promoter methylation in patients with grade II glioma treated with combined radiotherapy and temozolomide and highlights its potential prognostic value beyond IDH1/2 mutation status.
|
29955793 |
2018 |
estrogen receptor-negative breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
In ER negative breast cancer the MGMT promoter is frequently methylated.
|
30038716 |
2018 |
Malignant neoplasm of thyroid
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Further investigation is needed to decipher the functional properties of the methyltransferase encoded by MGMT and to understand how alteration of such functions may lead to the development of the most common type of thyroid cancer.
|
28499365 |
2017 |